Reviews/Rheumatoid Arthritis Targeted Therapy/TNF inhibitors improve response and slow radiographic progression in methotrexate-inadequate rheumatoid arthritis
TNF Biologics · RA-TNF-01 · v2
Several different anti-TNF drugs help a meaningful share of patients whose methotrexate alone was not enough, reaching the ACR50 mark that signals a substantial reduction in joint symptoms: infliximab in about 44 percent of patients [18], adalimumab around 48 percent [6], and a TNF fusion protein with methotrexate about 41 percent [3]. There is also evidence that anti-TNF treatment slows the joint damage seen on X-rays, with more treated patients showing no progression than those on methotrexate alone [11], and comparable damage scores under infliximab [18]. The two parts of the claim are therefore both supported by real anti-TNF data across multiple drugs. The weaker link is that much of the response data comes from trials designed to show a newer drug beating anti-TNF, where the anti-TNF arm is the one being outperformed [1][2]. The X-ray evidence is also less direct in the exact methotrexate-failure group, since the cleanest numbers come from early, methotrexate-naive patients [11]. The panel weighed a genuinely supported claim against these design and population caveats.
The corpus demonstrates ACR50 responses to multiple distinct TNF inhibitors in methotrexate-inadequate or active RA populations: infliximab at 43.6% [18], adalimumab at 48% [6], and a TNF-receptor fusion protein plus methotrexate at 41.3% [3]. Radiographic-progression inhibition is supported by adalimumab plus methotrexate, with 86% versus 72% of patients showing no progression at weeks 52 and 78 [11], and by comparable van der Heijde-modified Sharp scores under infliximab [18]. Adalimumab appears repeatedly as an active comparator that itself achieves ACR50 [1][4]. However, one head-to-head strategy trial reports a TNFi reaching only 20% ACR50 against baricitinib's 42% [2], and several papers sit off the exact population — active RA [3], csDMARD-failure [2], or reporting DAS28 rather than ACR50 [19]. The contested point: The evidence divides on the radiographic conjunct in the exact methotrexate-failure population: the one clean numeric benefit [11] is in methotrexate-naive early RA, and the 'comparable' infliximab result [18] is a biosimilar-equivalence read between two infliximabs rather than a demonstration against placebo or control. The panel also divides on framing, since much ACR50 data comes from trials where the TNFi is the losing comparator arm [1][2].
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Rheumatoid Arthritis Targeted Therapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Much of the ACR50 and radiographic evidence comes from adalimumab used as an active comparator in JAK-inhibitor superiority trials [1][4], where the TNFi is repeatedly the weaker arm (upadacitinib superior to adalimumab on ACR50 [1]; baricitinib 42% vs TNFi 20% [2]) — the corpus frames TNFi efficacy in a losing posture rather than as a clean positive demonstration.
The radiographic conjunct is weakly evidenced in the exact MTX-IR population: the only clean numeric benefit [11] is in MTX-naive early RA, and [18]'s 'comparable' radiographic result is a biosimilar-equivalence read between two infliximabs, not inhibition versus placebo/control. No corpus paper shows a TNFi beating a control on radiographic progression specifically in MTX-IR with a reported magnitude.
Where it remains uncertain. The radiographic benefit is cleanest in methotrexate-naive early RA [11] and the infliximab radiographic result is a biosimilar-equivalence comparison [18], with much ACR50 data drawn from trials where the TNFi is the weaker comparator arm [1][2].
Aleatory
Reported ACR50 ranges from 20% [2] to 48% [6], reflecting genuine variation across patients, designs and settings.
Epistemic
The corpus contains no placebo-controlled TNFi pivotal reporting both ACR50 and radiographic progression in the methotrexate-inadequate population.
Inferential
The clean radiographic benefit [11] is in methotrexate-naive early RA and must be extrapolated to methotrexate-inadequate responders; [18]'s comparable result is a biosimilar-equivalence read, not inhibition versus control.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Confirms adalimumab (TNFi) is an ACR50-active comparator in MTX-IR RA with radiographic progression assessed, though framed as inferior to upadacitinib.
“Upadacitinib was superior to adalimumab based on the ACR50 response rate, achievement of a DAS28-CRP score of ≤3.2, change in pain severity score, and change in the Health Assessment Questionnaire disability index.”
Panel auditInternal validity: high · scope of inference: Efficacy of upadacitinib versus placebo and versus adalimumab in MTX-inadequate responders with RA.Key limitations: TNF inhibitor not compared to placebo · adalimumab ACR50 not reported numerically · radiographic result reported only for upadacitinib
Shows a TNFi strategy achieves ACR50 (20%) but underperforms a JAK inhibitor — establishes the lower bound and magnitude variance of the ACR50 conjunct.
“Baricitinib was both non-inferior and superior in achieving ACR50 response at week 12 (42% vs 20%).”
Panel auditInternal validity: medium · scope of inference: Comparative effectiveness of a baricitinib-first versus TNFi-first strategy in b/tsDMARD-naive RA after csDMARD failure.Key limitations: no placebo arm · TNFi is the comparator, not the tested agent · radiographic secondary result not in abstract
TNFi+MTX (etanercept-type fusion) achieves ACR50 41.3% — an independent molecule supporting the ACR50 conjunct.
“ACR50 was achieved in 57.1% (72/126), 41.3% (52/126), 23.0% (29/126), and 26.2% (33/126) patients receiving TwHF+rhTNFR-Fc, MTX + rhTNFR-Fc, TwHF and MTX monotherapy, respectively, at week 12”
Panel auditInternal validity: medium · scope of inference: ACR50 at week 12 in active RA patients across TNF-receptor and MTX combinations.Key limitations: population not defined as MTX-inadequate responders · significance not stated for the TNFi-vs-MTX contrast · no radiographic outcome
The abstract gives only filgotinib's non-inferiority to adalimumab on DAS28-CRP; the TNF inhibitor's own ACR50 and radiographic outcomes are not separately reported.
Panel auditInternal validity: high · scope of inference: Filgotinib efficacy versus placebo and versus adalimumab in MTX-inadequate responders with RA.Key limitations: TNFi arm results not separately reported · no adalimumab-vs-placebo ACR50 or radiographic figure
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Both conjuncts are genuinely carried by primary TNFi data across several molecules, but comparator-arm framing, wide ACR50 variance, and an indirect radiographic conjunct hold it below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Placebo-controlled radiographic endpoint in methotrexate-failure RA. No corpus paper shows a TNFi inhibiting radiographic progression versus control specifically in methotrexate-inadequate responders with a reported magnitude. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised placebo-controlled TNFi trial in methotrexate-inadequate responders reporting van der Heijde-modified Sharp progression as a primary endpoint.
Open question: Does a TNF inhibitor inhibit radiographic progression versus control specifically in methotrexate-inadequate responders? Why it is still open: The only clean numeric radiographic benefit [11] is in methotrexate-naive early RA and [18]'s comparable result is a between-infliximab equivalence read, not an inhibition-versus-control demonstration in the target population.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19